2^nd International Conference on Cancer Genetics and Epigenetics November 12-13, 2018 | Radisson Hotel Narita | Tokyo, Japan

Biography:

Xiaoying Cui has completed her PhD in 2004 from Harbin Medical University and Singapore General Hospital.  Her postdoctoral studies are at the Queensland Brain Institute, the University of Queensland. She is currently a senior research fellow in the Neurodevelopmental Group in the Queensland Brain Institute. She has published more than 31 papers in reputed journals, which attracted over 1480 citations (Google Scholar) and has been serving as reviewer for multiple renowned journals.

Abstract:

Neuroblastoma is a severe disorder that affects infant and young children. The survival rates of the patients with highly aggressive tumour is less than 50%, despite intensive multimodal therapy. Recently, a growth body of evidence have shown that noncoding RNAs played critical role in the tumour growth and are now the novel drug targets for multiple tumours. Long intergenic noncoding RNA HOX-antisense intergenic RNA myeloid 1 (HOTAIRM1) had been found to be associated with a few cancers including leukemia, colon cancer and breast cancer. In this study, we showed that low HOTAIRM1 was expressed at low abundance in human and mouse neuroblastoma. Knockdown HOTAIRM1 altered cell cycle progression and delayed the retinoic acid-induced dopaminergic differentiation of human SHSY5Y cells. The dopamine related genes including tyrosine hydroxylase (the rate limiting enzyme for dopamine synthesis and dopamine neuronal marker), vesicular monoamine transporter 2 and monoamine oxidase were reduced by HOTAIRM1 attenuation. Furthermore, we observed a dramatic increase in the number of caspase 3 positive cells when HOTAIRM1 was decreased, suggesting reduction of HOTAIRM1 could lead to apoptosis of human neuroblastoma. We also found that reducing HOTAIRM1 modulated DNA methylation and histone methylation, indicating that HOTAIRM1 modulate cell proliferation, differentiation and apoptosis via epigenetic pathways. Collectively, we revealed that noncoding RNA HOTAIRM1 modulates the growth and apoptosis of human and mouse neuroblastomas. This noncoding RNA could be a potential therapeutic target in the treatment of human neuroblastoma.  

 

Biography:

She is a Biotechnologist working in The society for Infertility Sciences, Avicenna Research centre, Tehran, Iran. She completed her medical studies in Genetic engineering at Rudehen Azad University, Tehran, Iran. She has published more than 10 papers in reputed journals and has been serving as an editorial board member of repute.

Abstract:

Cervical cancer is a type of cancer that started from the cervix of rheum and it spreads to other parts of the textures of the target or other organs. Across the world, this type of cancer is the fourth leading cause of death in women, According to the global statistics out of every 528000, 266000 deaths have been reported that occurs mostly in developing countries. Chemotherapy and radiotherapy are commonly used in this cancer, as you know, chemotherapy-based treatments will have very serious side effects for the body and may cause serious damage to healthy cells close to the tumor during the removal of cancer cells.

According to researches and expert studies on effective methods for the delivery of therapeutic drugs to tumors and adequate knowledge of the structure and function of sperms, recently, we have come to the conclusion that these mobile cells can be used to deliver medications to the tumor site. This method has many advantages, including the packaging of the drug for treating cervical cancer that this makes it so do not dilute medications in body fluids and do not leak out and also the desired medication keep away from existing enzymes and they do not stimulate the immune response. Another advantage of this treatment method is that Sperms are inherently motile and could transmit them exactly to the place of the tumors by magnetic panels that added to these drug carriers until according to their normal function release the drug into tumors in the cervix that this causes to the drug reach to deeper cancer cells in the masses. This therapeutic mechanism has been a very low risk and currently, it is under experimentally discussion and research.